Dermata Therapeutics is preparing to launch its first commercial product, Tome Foundational Treatment, on August 25, 2026, as the company completes a strategic transformation from pharmaceutical development into a commercial-stage, direct-to-consumer skincare business.
The launch comes with a relatively limited financial runway. Dermata ended the second quarter with $4.4 million in cash and cash equivalents, down from $7.5 million at the end of 2025. Management expects its existing cash resources to fund operations into the fourth quarter of 2026.
During the first half of the year, Dermata used $4.9 million of cash in operating activities and $0.1 million in investing activities. Those outflows were partially offset by approximately $1.9 million of proceeds raised through the company’s at-the-market financing program.
Dermata has completed manufacturing and packaging for Tome Foundational Treatment and said it is prepared for the commercial rollout. The once-weekly product is designed to renew the appearance of skin while simplifying consumers’ skincare routines.
The Tome line incorporates Dermata’s Bioneedle technology, which uses Spongilla lacustris, a wild-harvested freshwater sponge, as a primary ingredient. The company is positioning the brand around science-based skincare intended to deliver results without the recovery associated with certain in-office treatments.
Dermata introduced the Tome brand publicly at the Be+Well Beauty and Wellness Show in Las Vegas in June. The company has also launched a social media campaign intended to build brand awareness and support the e-commerce introduction of Tome Foundational Treatment.
The strategic transition is also reshaping Dermata’s expense structure. Q2 research and development expenses declined to $0.2 million from $0.6 million a year earlier as the company redirected resources toward commercialization. Dermata expects R&D spending to continue declining compared with prior periods as employees and capital are shifted toward branding, marketing and manufacturing.
Selling, general and administrative expenses moved in the opposite direction, increasing to $2.8 million from $1.2 million. The increase included approximately $0.6 million of additional marketing and commercialization expenses, $0.7 million of higher legal fees and $0.3 million of increased employee compensation associated with the reallocation of personnel toward pre-commercial activities.
Total Q2 operating expenses increased to $3 million from $1.8 million, and Dermata’s net loss widened to approximately $3 million from $1.7 million. For the first six months, the company reported a net loss of $4.8 million compared with $4 million a year earlier.
The company’s balance sheet is also beginning to reflect its transition into a product-selling business. Inventory reached $150,000 at June 30 compared with no inventory at the end of 2025, consistent with Dermata completing production ahead of the Tome launch.
Dermata is already developing a second consumer product. The company plans a once-weekly over-the-counter topical acne treatment that is expected to launch sometime after Tome Foundational Treatment.
Management believes the DTC model can ultimately support a broader portfolio rather than a single-product business. Dermata intends to use direct consumer relationships and data-driven insights to refine marketing, increase customer engagement and introduce additional skincare products over time.
KEY QUOTES:
“Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company. This transition has been marked by significant execution across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect to start selling on August 25, 2026.”
“Looking ahead, we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement, and efficiently expand our product portfolio over time.”
Gerry Proehl, Chairman, President And CEO Of Dermata Therapeutics
